Pipeline & Medicines Explore the Science of Possibility View Vertex Research Giving BackLearn more about our STEM Program, Volunteer Efforts, Grants and Funding./giving-back Recent UpdatesFDA Approves SYMDEKOExpanded EU Approval for ORKAMBIKALYDECO Approved for Additional Mutations The Stories Behind Vertex: Science European Commission grants Marketing Authorization for SYMKEVI® (tezacaftor/ivacaftor) Giving Back The Vertex Foundation Commits $5 Million to i2 Learning to Expand STEM Education Opportunities for Students Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis Science Our Commitment to Research & Development Science Vertex Celebrates the 50th Science and Medicine Seminar We Are Vertex Vertex’s Michael Parini Is Moved to Make a Difference Giving Back How Vertex’s New Discovery Camp Makes Summertime Learning Sizzle All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project × We Are Vertex Day of Service × All in for CF Amanda and Peter Krug Share Their Perspective on What It Takes To Care for Harry, Their 10-Year-Old Son Who Is Living with Cystic Fibrosis Explore More Stories @vertexpharma
Giving Back The Vertex Foundation Commits $5 Million to i2 Learning to Expand STEM Education Opportunities for Students
Science Vertex Initiates Second Phase 3 VX-659 Triple Combination Study in Certain People with Cystic Fibrosis
All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project
× All in for CF Amanda and Peter Krug Share Their Perspective on What It Takes To Care for Harry, Their 10-Year-Old Son Who Is Living with Cystic Fibrosis
